2 June 2016 - Afinitor fills critical need in EU as first approved therapy for advanced, progressive, non-functional lung neuroendocrine tumour and first oral therapy for this type of gastro-intestinal neuroendocrine tumour.

Novartis announced today that the European Commission has approved Afinitor (everolimus) tablets for the treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) nonfunctional neuroendocrine tumors (NET) of gastro-intestinal (GI) or lung origin in adults with progressive disease.

Afinitor is the first approved therapy in all 28 member states of the EU, plus Iceland and Norway, for this type of lung NET, and one of very few treatment options available for this type of GI NET.

For more details, go to: https://www.novartis.com/news/media-releases/novartis-drug-afinitorr-receives-eu-approval-treat-certain-types-advanced